MetaCap

Xenon Pharmaceuticals Inc. (XENE)

NASDAQ: XENEHealth CareBiotechnology: Pharmaceutical PreparationsUSD

37.04-0.52 (-1.38%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

XENE stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$4.69
52-week range
33.38 – 72.66
Day range
36.81 – 37.97
Volume / Avg
1.09M / 1.69M
Beta
—

52-week range

$33.38$72.66

XENE stock today

Shares of Xenon Pharmaceuticals (XENE) finished lower on Nov 20 at $37.04, a drop of 1.38% or $0.52 per share, versus the S&P 500's 3.70% decline. At this level, XENE sits near the bottom of its 52-week range of $33.38 to $72.66: 49.0% below the high, set on Jul 9, 2026 and 11.0% above the low. XENE is down 17.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 10.0%.

Xenon Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$4.69), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Xenon Pharmaceuticals

Company profile

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
Headquarters
Burnaby, BC
Employees
358
IPO year
2014

Financial highlights

Full financials

In fiscal 2025, Xenon Pharmaceuticals generated $7.5 million in revenue, up 0.0% from fiscal 2024. Xenon Pharmaceuticals reported a net loss of $345.9 million, compared with a loss of $234.3 million a year earlier. Operating margin was -4974.3%.

Xenon Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$7.50M$0$0$9.43M$18.44M
Growth——-100.00%-48.83%-42.68%
Net income$-345.91M$-234.33M$-182.39M$-125.37M$-78.88M
EPS (diluted)$-4.36$-3.01$-2.73$-2.06$-1.77

Analyst forecast

Forecast

Consensus (18 analysts)

strong_buy

Avg. price target

$71.69+93.55%

  • Strong buy 3
  • Buy 14
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $46.00High $90.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-1.15 vs $-1.14
Surprise
-0.88%

XENE news

All XENE news

Xenon Pharmaceuticals peers

Health Care sector
XENE peer companies
CompanyPrice% ChgMarket capCompare
TNGXTango Therapeutics Inc.21.73-4.32%$3.68Bvs XENE
OGNOrganon & Co.13.89-0.14%$3.65Bvs XENE
PBLSParabilis Medicines Inc.27.44-0.67%$3.44Bvs XENE
ELVNEnliven Therapeutics Inc.46.53+0.26%$3.42Bvs XENE
IRONDisc Medicine Inc.75.14-1.27%$3.42Bvs XENE
VRDNViridian Therapeutics Inc.29.96-4.71%$3.40Bvs XENE
AMLXAmylyx Pharmaceuticals Inc.26.02-0.69%$3.35Bvs XENE
ARQTArcutis Biotherapeutics Inc.26.36-2.98%$3.33Bvs XENE

Indexes, lists and sector

Xenon Pharmaceuticals stock FAQ

What is Xenon Pharmaceuticals's stock price today?

XENE last traded at $37.04 as of Nov 20, 4:00 PM EST, down 1.38% on the day. Prices are delayed at least 15 minutes.

Who is Xenon Pharmaceuticals's CEO?

Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. is the chief executive officer of Xenon Pharmaceuticals Inc., which has about 358 employees.

What is the XENE 52-week high?

The 52-week high for XENE is $72.66 and the 52-week low is $33.38. The stock is currently 49.0% below its high.

Compare XENE